LIA
MRNA icon

Lynx Investment Advisory’s Moderna MRNA Stock Holding History

Lynx Investment Advisory’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-800
Closed -$95K – 524
2024
Q2 		$95K Buy
+800
New +$101K 0.07% 183

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lynx Investment Advisory's MRNA Position: Q3 2024 in Review

Lynx Investment Advisory sold out of Moderna (MRNA) in Q3 2024, closing a stake of 800 shares — an estimated $95K sold.

Lynx Investment Advisory first reported a position in MRNA in Q2 2024 and held it in 1 quarter. The position peaked at $95K in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Lynx Investment Advisory reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Lynx Investment Advisory sold 800 Moderna shares in Q3 2024, an estimated $95K.
  • Lynx Investment Advisory first reported a position in Moderna in Q2 2024 and held it in 1 quarter.
  • Lynx Investment Advisory's Moderna position peaked at $95K in Q2 2024.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Lynx Investment Advisory's 13F filing for Q3 2024, filed 4 Nov 2024.